Clinical Trials
13
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:11
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (84.6%)Phase 2
1 (7.7%)Phase 3
1 (7.7%)A Study of BR111 in Patients With Advanced Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: BR111 for Injection
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT06937957
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cancer, Shang Hai, Pudong New Area, China
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Phase 2
Not yet recruiting
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06642909
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: BR115 for injection
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06388902
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BRY805 in Participants With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: BRY805 injection
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06289894
- Locations
- 🇨🇳
Shandong Tumor hospital, Jinan, Shandong, China
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06126718
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- Prev
- 1
- 2
- 3
- Next
News
BioRay's Novel Dual-Epitope ADC Drug BR111 Advances to Clinical Trials for Cancer Treatment
BioRay Pharmaceutical's innovative BR111, the world's first anti-ROR1 Bi-paratopic ADC, has received clinical trial approval from China's NMPA for treating ROR1-positive cancers.